Articles tagged with: NeoRecormon
This year’s American Society of Clinical Oncology (ASCO) annual meeting was held from last Friday through this Tuesday in Chicago.
Results from a number of important studies related to myelodysplastic syndromes (MDS) were presented during the meeting. Several of those studies were covered in an oral presentation session on Tuesday, which is the subject of this article.
A previous Beacon meeting update covered additional studies presented during poster sessions at ASCO last Saturday and Sunday.
All Beacon ASCO updates are based on the actual presentations and posters presented at the …
Results of a French Phase 2 clinical trial indicate that the addition of the anemia drug NeoRecormon may help lower-risk myelodysplastic syndromes patients better tolerate treatment with Vidaza.
However, the French researchers did not observe any differences in outcomes between patients who received NeoRecormon plus Vidaza and patients who received Vidaza alone.
The results were presented earlier this month at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.…